Clean Yield Group Increases Holdings in Sanofi SA (SNY)

Share on StockTwits

Clean Yield Group raised its position in shares of Sanofi SA (NYSE:SNY) by 2.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 110,967 shares of the company’s stock after acquiring an additional 2,420 shares during the period. Sanofi accounts for 2.0% of Clean Yield Group’s investment portfolio, making the stock its 9th biggest position. Clean Yield Group’s holdings in Sanofi were worth $4,957,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in SNY. Institute for Wealth Management LLC. grew its holdings in shares of Sanofi by 27.4% during the 2nd quarter. Institute for Wealth Management LLC. now owns 31,936 shares of the company’s stock valued at $1,278,000 after acquiring an additional 6,860 shares in the last quarter. Van ECK Associates Corp grew its holdings in shares of Sanofi by 15.1% during the 2nd quarter. Van ECK Associates Corp now owns 361,195 shares of the company’s stock valued at $14,451,000 after acquiring an additional 47,420 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Sanofi by 32.0% during the 2nd quarter. Signaturefd LLC now owns 10,266 shares of the company’s stock valued at $411,000 after acquiring an additional 2,486 shares in the last quarter. Nomura Holdings Inc. grew its holdings in shares of Sanofi by 51.8% during the 2nd quarter. Nomura Holdings Inc. now owns 50,726 shares of the company’s stock valued at $2,030,000 after acquiring an additional 17,310 shares in the last quarter. Finally, Providence Capital Advisors LLC grew its holdings in shares of Sanofi by 46.0% during the 2nd quarter. Providence Capital Advisors LLC now owns 30,016 shares of the company’s stock valued at $1,201,000 after acquiring an additional 9,460 shares in the last quarter. 7.53% of the stock is currently owned by institutional investors.

NYSE:SNY traded down $0.01 during trading hours on Monday, reaching $44.56. The company’s stock had a trading volume of 66,363 shares, compared to its average volume of 1,369,484. The stock has a market capitalization of $111.79 billion, a PE ratio of 14.25, a P/E/G ratio of 2.44 and a beta of 0.82. Sanofi SA has a one year low of $37.43 and a one year high of $49.81. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40.

Sanofi (NYSE:SNY) last issued its quarterly earnings data on Tuesday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.02. The firm had revenue of $8.18 billion during the quarter, compared to analysts’ expectations of $8.27 billion. Sanofi had a net margin of 10.29% and a return on equity of 23.77%. Sanofi’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.35 earnings per share. On average, sell-side analysts forecast that Sanofi SA will post 3.11 earnings per share for the current fiscal year.

In related news, major shareholder Sanofi sold 104,552 shares of the company’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.00% of the company’s stock.

SNY has been the subject of a number of recent research reports. ValuEngine upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Wednesday, October 17th. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. Guggenheim initiated coverage on shares of Sanofi in a report on Monday, October 8th. They issued a “neutral” rating for the company. BNP Paribas upgraded shares of Sanofi from a “neutral” rating to an “outperform” rating in a report on Wednesday, August 1st. Finally, Deutsche Bank reiterated a “buy” rating on shares of Sanofi in a report on Wednesday, August 1st. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $49.00.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Read More: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply